Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)

NCT00390832 is registered in ClinicalTrials.gov with Deutsches Herzzentrum Muenchen as lead sponsor.

NCT NCT00390832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)
Lead sponsor
Deutsches Herzzentrum Muenchen
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2009
Enrollment
138 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

angioplasty, transluminal, percutaneous coronary, myocardial infarction